6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidine | 1062368-61-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidine
• 英文别名: ML347 Analog
• CAS: 1062368-61-9
• 化学式: C₁₃H₁₁N₃O
• 分子量: 225.25
• InChiKey: VERQSLXHYIALTN-UHFFFAOYSA-N

物化性质

• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  39.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidine 在 N-碘代丁二酰亚胺 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium acetate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 28.0h， 生成 6-(4-methoxyphenyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyrimidine
  参考文献：
  名称：

  Synthesis and structure–activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of Dorsomorphin: The discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe

  摘要：

  A structure-activity relationship of the 3- and 6-positions of the pyrazolo[1,5-a] pyrimidine scaffold of the known BMP inhibitors dorsomorphin, 1, LDN-193189, 2, and DMH1, 3, led to the identification of a potent and selective compound for ALK2 versus ALK3. The potency contributions of several 3-position substituents were evaluated with subtle structural changes leading to significant changes in potency. From these studies, a novel 5-quinoline molecule was identified and designated an MLPCN probe molecule, ML347, which shows >300-fold selectivity for ALK2 and presents the community with a selective molecular probe for further biological evaluation. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.03.113
• 作为产物：
  描述：

  6-溴-吡唑[1,5-a]咪唑 、 4-甲氧基苯硼酸 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 4.0h， 以82%的产率得到6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidine
  参考文献：
  名称：

  一种合成骨形态发生蛋白受体抑制剂的方法

  摘要：

  本发明公开的是一种合成骨形态发生蛋白受体抑制剂的方法，本发明解决了现有技术中抑制剂合成路线较长的问题。本发明包括(1)获得式(Ⅲ)所示中间体，式(Ⅲ)：其中，R1为或(2)向式(Ⅲ)所示中间体中加入5‑溴喹啉，再加入乙酸钾、醋酸钯，然后加入N,N‑二甲基乙酰胺反应，反应完成后冷却至室温；(3)当R1为时，加入水析出固体，干燥后分离即可获得产物一；当R1为时，反应液用乙酸乙酯萃取，有机相干燥除掉溶剂后，分离获得中间体IX，再将中间体IX溶于甲醇，并加入浓盐酸反应，完成后析出固体，固体经过抽滤、洗涤、干燥后得到产物二。本发明具有制备步骤更短、采用的原料价格更低、目的产物的收率更高等优点。

  公开号：

  CN105130991B

文献信息

• 10.1016/j.tet.2024.134020
  作者：Ohki, Hugo、Komatsuda, Masaaki、Kondo, Hiroki、Yamaguchi, Junichiro

  DOI：10.1016/j.tet.2024.134020

  日期：——

  We have developed a novel ring-opening difluorination process for pyrazoloazines. Utilizing 2.5 equivalents of Selectfluor®, this method enables electrophilic difluorination and subsequent ring-opening of pyrazoloazines, yielding the corresponding difluoroalkylated azines. Additionally, our protocol extends to the decarbonylative difluorination of pyrazoloazines when starting with a formyl group at

  我们开发了一种新型的吡唑并嗪开环二氟化工艺。该方法利用 2.5 当量的 Selectflu®，实现亲电二氟化和随后吡唑并嗪的开环，产生相应的二氟烷基化吖嗪。此外，我们的方案还扩展到以 C3 位甲酰基为起始的吡唑并嗪的脱羰二氟化，证明了该方法的多功能性和广泛适用性。二氟化化学的这一进步为二氟化化合物的合成提供了一条新途径，可能丰富药物化学和材料科学从业者的工具包。
• Structure–activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors
  作者：Gregory D. Cuny、Paul B. Yu、Joydev K. Laha、Xuechao Xing、Ji-Feng Liu、Carol S. Lai、Donna Y. Deng、Chetana Sachidanandan、Kenneth D. Bloch、Randall T. Peterson

  DOI：10.1016/j.bmcl.2008.06.052

  日期：2008.8

  A structure-activity relationship study of dorsomorphin, a previously identified inhibitor of SMAD 1/5/8 phosphorylation by bone morphogenetic protein (BMP) type 1 receptors ALK2, 3, and 6, revealed that increased inhibitory activity could be accomplished by replacing the pendent 4-pyridine ring with 4-quinoline. The activity contributions of various nitrogen atoms in the core pyrazolo[1,5-a]pyrimidine ring were also examined by preparing and evaluating pyrrolo[1,2-a] pyrimidine and pyrazolo[1,5-a] pyridine derivatives. In addition, increased mouse liver microsome stability was achieved by replacing the ether substituent on the pendent phenyl ring with piperazine. Finally, an optimized compound 13 (LDN-193189 or DM-3189) demonstrated moderate pharmacokinetic characteristics (e.g., plasma t(1/2) = 1.6 h) following intraperitoneal administration in mice. These studies provide useful molecular probes for examining the in vivo pharmacology of BMP signaling inhibition. (c) 2008 Elsevier Ltd. All rights reserved.
• Synthesis and structure–activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of Dorsomorphin: The discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe
  作者：Darren W. Engers、Audrey Y. Frist、Craig W. Lindsley、Charles C. Hong、Corey R. Hopkins

  DOI：10.1016/j.bmcl.2013.03.113

  日期：2013.6

  A structure-activity relationship of the 3- and 6-positions of the pyrazolo[1,5-a] pyrimidine scaffold of the known BMP inhibitors dorsomorphin, 1, LDN-193189, 2, and DMH1, 3, led to the identification of a potent and selective compound for ALK2 versus ALK3. The potency contributions of several 3-position substituents were evaluated with subtle structural changes leading to significant changes in potency. From these studies, a novel 5-quinoline molecule was identified and designated an MLPCN probe molecule, ML347, which shows >300-fold selectivity for ALK2 and presents the community with a selective molecular probe for further biological evaluation. (C) 2013 Elsevier Ltd. All rights reserved.
• 一种合成骨形态发生蛋白受体抑制剂的方法
  申请人：成都知普莱生物医药科技有限公司

  公开号：CN105130991B

  公开（公告）日：2017-09-19

  本发明公开的是一种合成骨形态发生蛋白受体抑制剂的方法，本发明解决了现有技术中抑制剂合成路线较长的问题。本发明包括(1)获得式(Ⅲ)所示中间体，式(Ⅲ)：其中，R1为或(2)向式(Ⅲ)所示中间体中加入5‑溴喹啉，再加入乙酸钾、醋酸钯，然后加入N,N‑二甲基乙酰胺反应，反应完成后冷却至室温；(3)当R1为时，加入水析出固体，干燥后分离即可获得产物一；当R1为时，反应液用乙酸乙酯萃取，有机相干燥除掉溶剂后，分离获得中间体IX，再将中间体IX溶于甲醇，并加入浓盐酸反应，完成后析出固体，固体经过抽滤、洗涤、干燥后得到产物二。本发明具有制备步骤更短、采用的原料价格更低、目的产物的收率更高等优点。